Poherdy is the first FDA-approved interchangeable biosimilar to Perjeta for HER2-positive breast cancer, potentially expanding access and reducing costs. Approved for use in combination with ...

Consolidates messaging around Einstein Rx AI, Wellgistics Hub (formerly DelivMeds) and HubRx AI integration with pharmacies (in-house pharmacy and 6,500+ independent pharmacy network), physicians and ...

Clinical development programs for doxorubicin-containing microneedle array (D-MNA) and Teverelix, a next generation GnRH ...

SynchNeuro is a Portfolio Company of Boomerang Ventures INDIANAPOLIS, IN / ACCESS Newswire / November 12, 2025 / Boomerang Ventures adds SynchNeuro, Inc. to its portfolio of seed-stage investments, ...

Through substantial leadership turnover and workforce cuts, the FDA has continued to support the advanced therapy sector, actively working to remove obstacles to innovation.

As deadly drug overdoses climbed across Canada, decision-makers faced political backlash for funding programs that gave drug ...

While AI has accelerated drug discovery, the same technology can address clinical trial bottlenecks that have persisted for ...

JERUSALEM, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera” or the "Company”), a leader in the ...

FDA Type 2a meeting scheduled for November 19, 2025, to review AEON's analytical development plan and initial data - - Positive biosimilarity data for ABP-450 confirming identical amino-acid sequencin ...

Presidents Donald J. Trump (United States) and Javier Milei (Argentina) announced on Thursday a “Framework for a Reciprocal ...

Kyverna Therapeutics (KYTX) is rated a strong buy with promising KYV-101 Phase 2 data and near-term catalysts. Read here for ...

New data on causes of death reveals more than 17,500 people died of dementia in 2024 nationwide, according to the Australian ...